Neurocrine Biosciences (NBIX) Free Cash Flow (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Free Cash Flow of $128.6 million for Q2 2026, up 43.69% year-over-year from $89.5 million in Q2 2025, and down 5.93% on a QoQ basis from $136.7 million in Q1 2026.
Neurocrine Biosciences (NBIX) Free Cash Flow (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Free Cash Flow for 17 years, with the latest figure at $128.6 million in Q2 2026.
- Free Cash Flow for Q2 2026 came in at $128.6 million, up 43.69% year-over-year; the trailing twelve-month figure through Jun 2026 was $870.4 million (up 64.63% YoY), and the FY2025 annual result was $748.7 million, up 34.37% from the prior year.
- Free Cash Flow fell to $128.6 million in Q2 2026, from $136.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $390.8 million in Q4 2025 and troughed at -$133.7 million in Q1 2023.
- A 5-year average of $125.3 million and a median of $129.0 million in 2022 frame the typical range for Free Cash Flow.
- The widest annual swing landed in 2022, when Free Cash Flow jumped 3104.26%; it then sank 177.96% in 2023.
- A 5-year view of Free Cash Flow shows it stood at $141.2 million in 2022, then retreated by 16.36% to $118.1 million in 2023, then soared by 99.15% to $235.2 million in 2024, then jumped by 66.16% to $390.8 million in 2025, then plunged by 67.09% to $128.6 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were $128.6 million in Q2 2026, $136.7 million in Q1 2026, and $390.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 137.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128.60 Mn |
| Jun 30, 2026 | 128.60 Mn |
| Mar 31, 2026 | 144.40 Mn |
| Mar 31, 2026 | 144.40 Mn |
| Dec 31, 2025 | 390.80 Mn |
| Dec 31, 2025 | 390.80 Mn |
| Sep 30, 2025 | 193.00 Mn |
| Sep 30, 2025 | 193.00 Mn |
| Jun 30, 2025 | 110.80 Mn |
| Jun 30, 2025 | 110.80 Mn |
| Mar 31, 2025 | 54.10 Mn |
| Mar 31, 2025 | 54.10 Mn |
| Dec 31, 2024 | 205.10 Mn |
| Dec 31, 2024 | 205.10 Mn |
| Sep 30, 2024 | 160.50 Mn |
| Sep 30, 2024 | 160.50 Mn |
| Jun 30, 2024 | 72.50 Mn |
| Jun 30, 2024 | 72.50 Mn |
| Mar 31, 2024 | 119.10 Mn |
| Mar 31, 2024 | 119.10 Mn |